These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19402389)

  • 1. Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies.
    Tuna B; Unlu M; Aslan G; Secil M; Yorukoglu K
    Anal Quant Cytol Histol; 2009 Apr; 31(2):118-22. PubMed ID: 19402389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
    Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
    Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.
    Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R
    J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
    Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
    Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
    Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
    Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
    Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezrin immunoreactivity in renal cell carcinomas.
    Tuna B; Yorukoglu K; Mazzucchelli R; Mungan U; Secil M; Montironi R; Kirkali Z
    Anal Quant Cytol Histol; 2009 Oct; 31(5):340-4. PubMed ID: 20701102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal tumor with alpha B crystallin expression.
    Kim MS; Lee HW; Lee EH
    Int J Clin Exp Pathol; 2015; 8(8):9383-9. PubMed ID: 26464692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary carcinoma of renal calyx.
    Williams PA; Mai KT
    Pathol Res Pract; 2013 Oct; 209(10):654-61. PubMed ID: 23999038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD10 is a diagnostic and prognostic marker in renal malignancies.
    Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
    Histopathology; 2004 Nov; 45(5):460-7. PubMed ID: 15500649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
    Mohammed KH; Siddiqui MT; Cohen C
    Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
    Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
    Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characterization and staging of renal tumors: significance of MRI diagnostics].
    Kalinka A; Gerlach A; Arlart IP; Günes N; Hauser TK; Würstlin S; Bosse A
    Rofo; 2006 Mar; 178(3):298-305. PubMed ID: 16508837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
    Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
    Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
    Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
    Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.